An experimental compound called AP503 significantly strengthened bones in mice by activating GPR133. GPR133 is a receptor that boosts bone formation while slowing bone loss. This discovery offers a potential new pathway for treating osteoporosis.
Osteoporosis weakens bones and increases fracture risk. Millions of people are affected. Current therapies have limitations and side effects. Researchers are seeking new biological targets for more effective treatments. Scientists at Leipzig University identified GPR133 as one such target.
GPR133 is an adhesion G protein-coupled receptor. These receptors are on cell surfaces and help cells respond to signals. The new findings suggest GPR133 is crucial for building and maintaining healthy bone. Genetic changes impairing GPR133 in mice lead to early bone density loss. This is similar to human osteoporosis. Activating GPR133 with AP503 increased bone strength in both healthy and osteoporotic mice.
GPR133 responds to physical forces and interactions between bone cells. Its activation changes the balance between bone-building cells (osteoblasts) and bone-resorbing cells (osteoclasts). This shifts the balance toward stronger bone. AP503 mimics this natural activation process. This suggests it could increase bone strength or restore weakened bone. This could be particularly useful for osteoporosis linked to menopause.
AP503 may also affect muscles. An earlier study found that AP503 activation strengthens skeletal muscle. A treatment improving both bone and muscle strength could benefit older adults. They often experience declines in both tissues. Stronger muscles support mobility and stability. Stronger bones reduce fracture vulnerability. Researchers are now exploring GPR133's broader functions and AP503's potential in other diseases.
Related stories
Dreaming May Deplete Brain Energy Despite Increased Fuel Supply
New research indicates that dreaming during REM sleep may consume significant brain energy, with neuronal energy levels dropping despite an increase in the brain's fuel supply.
Tirzepatide May Activate Calorie-Burning Brown Fat
A mouse study suggests tirzepatide, sold as Mounjaro and Zepbound, may activate calorie-burning brown fat, offering a new understanding of its metabolic benefits.
ADHD and Autism Diagnoses Show Shifting Demographics in Denmark
A large Danish study found that children diagnosed with ADHD or autism now more closely resemble the general population, suggesting broader identification rather than only an increase in underlying conditions.